scispace - formally typeset
D

David J. Brinkman

Researcher at University of Amsterdam

Publications -  23
Citations -  634

David J. Brinkman is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Medicine & Competence (human resources). The author has an hindex of 7, co-authored 17 publications receiving 391 citations. Previous affiliations of David J. Brinkman include Vanderbilt University Medical Center.

Papers
More filters
Journal ArticleDOI

Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2) : a multicentre, patient-blinded, randomised controlled phase 2/3 trial

Jony van Hilst, +99 more
TL;DR: This multicentre, patient-blinded, parallel-group, randomised controlled phase 2/3 trial was performed in four centres in the Netherlands to assess whether laparoscopic pancreatoduodenectomy could reduce time to functional recovery compared with open pancreatic fistula.
Journal ArticleDOI

Outcomes of a Multicenter Training Program in Laparoscopic Pancreatoduodenectomy (LAELAPS-2).

TL;DR: This LPD training program was feasible and ensured acceptable outcomes during the learning curve in all centers, and future studies should determine whether such a training program is applicable in other settings and assess the added value of LPD.
Journal ArticleDOI

Neuroimmune Interactions in the Gut and Their Significance for Intestinal Immunity.

TL;DR: Current knowledge on the innervation of the gut, the potential of cholinergic and adrenergic systems to modulate intestinal immunity, and the ongoing developments in clinical trials are reviewed.
Journal ArticleDOI

Benchmarking recent national practice in rectal cancer treatment with landmark randomized controlled trials

Wilfred A. Borstlap, +171 more
- 01 Mar 2017 - 
TL;DR: This study showed that current rectal cancer care in a large unselected Dutch population is of high quality, with less positive CRM since the TME trial and oncologically safe implementation of minimally invasive surgery after the COLOR II trial.